Analysis of Specialized DNA Polymerases Expression in Human Gliomas: Association with Prognostic Significance

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2010 Feb 19

PMID 20164241

Citations 51

Authors

Huibo Wang

Wenting Wu

Hong-Wei Wang

Shuai Wang

Yuanyuan Chen

Xiaotian Zhang

Jingmin Yang

Shiguang Zhao

Han-Fei Ding

Daru Lu

Affiliations

Soon will be listed here.

Abstract

Aberrant activation of the translesion DNA synthesis (TLS) pathway has been suggested to play a role in tumorigenesis by promoting genetic mutations. We therefore examined glioma specimens for the expression of specialized DNA polymerases involved in TLS and assessed their prognostic significance. The expression levels of DNA polymerase κ (Pol κ), Pol ι, and Pol η were assessed in 40 primary glioma samples and 10 normal brain samples using quantitative real-time PCR and Western blot analysis. Their prognostic significance was evaluated using a population-based tissue microarray derived from a cohort of 104 glioma patients. Overexpression of Pol κ and Pol ι was observed in 57.5% (23-40) and 27.5% (11-40) of patients, respectively, whereas no significant expression of Pol η was seen in the specimens. Immunohistochemical studies revealed positive Pol κ and Pol ι staining in 72 (69.2%) and 33 (31.7%) of the 104 glioma specimens, respectively. Pol κ expression was associated with advanced stages of the disease. Both Pol κ- and Pol ι-positive staining were associated with shorter survival in glioma patients (P < .001 and P = .014, respectively). A multivariate survival analysis identified Pol κ as an independent prognostic factor for glioma patients (P < .001). These findings demonstrate, for the first time, that the expression of Pol κ and Pol ι is deregulated in gliomas, and upregulation of Pol κ is associated with poorer prognosis in glioma patients.

Citing Articles

AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma.

Bickerdike M, Nafia I, Bessede A, Chen C, Wangpaichitr M BMC Cancer. 2024; 24(1):889.

PMID: 39048947 PMC: 11267968. DOI: 10.1186/s12885-024-12631-w.

Human translesion DNA polymerases ι and κ mediate tolerance to temozolomide in MGMT-deficient glioblastoma cells.

Latancia M, da Silva Leandro G, Bastos A, Moreno N, Ariwoola A, Martins D DNA Repair (Amst). 2024; 141:103715.

PMID: 39029375 PMC: 11330349. DOI: 10.1016/j.dnarep.2024.103715.

Temozolomide resistance mechanisms: unveiling the role of translesion DNA polymerase kappa in glioblastoma spheroids in vitro.

Ribeiro D, Latancia M, de Souza I, Ariwoola A, Mendes D, Rocha C Biosci Rep. 2024; 44(5).

PMID: 38717250 PMC: 11139666. DOI: 10.1042/BSR20230667.

Adaptive use of error-prone DNA polymerases provides flexibility in genome replication during tumorigenesis.

Bainbridge L, Daigaku Y Cancer Sci. 2024; 115(7):2125-2137.

PMID: 38651239 PMC: 11247608. DOI: 10.1111/cas.16188.

Implications of Translesion DNA Synthesis Polymerases on Genomic Stability and Human Health.

Venkadakrishnan J, Lahane G, Dhar A, Xiao W, Bhat K, Pandita T Mol Cell Biol. 2023; 43(8):401-425.

PMID: 37439479 PMC: 10448981. DOI: 10.1080/10985549.2023.2224199.

References

Zhao B, Wang J, Geacintov N, Wang Z . Poleta, Polzeta and Rev1 together are required for G to T transversion mutations induced by the (+)- and (-)-trans-anti-BPDE-N2-dG DNA adducts in yeast cells. Nucleic Acids Res. 2006; 34(2):417-25. PMC: 1331986. DOI: 10.1093/nar/gkj446. View

Loeb L, Loeb K, Anderson J . Multiple mutations and cancer. Proc Natl Acad Sci U S A. 2003; 100(3):776-81. PMC: 298677. DOI: 10.1073/pnas.0334858100. View

Wang H, Zhang S, Wang S, Lu J, Wu W, Weng L . REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. Neuro Oncol. 2009; 11(6):790-802. PMC: 2802399. DOI: 10.1215/15228517-2009-015. View

Wang Y, Seimiya M, Kawamura K, Yu L, Ogi T, Takenaga K . Elevated expression of DNA polymerase kappa in human lung cancer is associated with p53 inactivation: Negative regulation of POLK promoter activity by p53. Int J Oncol. 2004; 25(1):161-5. View

Lin X, Trang J, Okuda T, Howell S . DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clin Cancer Res. 2006; 12(2):563-8. DOI: 10.1158/1078-0432.CCR-05-1380. View

Ogi T, Mimura J, Hikida M, Fujimoto H, Fujii-Kuriyama Y, Ohmori H . Expression of human and mouse genes encoding polkappa: testis-specific developmental regulation and AhR-dependent inducible transcription. Genes Cells. 2001; 6(11):943-53. DOI: 10.1046/j.1365-2443.2001.00478.x. View

Ohashi E, Bebenek K, Matsuda T, Feaver W, Gerlach V, Friedberg E . Fidelity and processivity of DNA synthesis by DNA polymerase kappa, the product of the human DINB1 gene. J Biol Chem. 2000; 275(50):39678-84. DOI: 10.1074/jbc.M005309200. View

Okada T, Sonoda E, Yoshimura M, Kawano Y, Saya H, Kohzaki M . Multiple roles of vertebrate REV genes in DNA repair and recombination. Mol Cell Biol. 2005; 25(14):6103-11. PMC: 1168817. DOI: 10.1128/MCB.25.14.6103-6111.2005. View

Lengauer C, Kinzler K, Vogelstein B . Genetic instabilities in human cancers. Nature. 1999; 396(6712):643-9. DOI: 10.1038/25292. View

10.

Wen P, Kesari S . Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507. DOI: 10.1056/NEJMra0708126. View

11.

Ohashi E, Ogi T, KUSUMOTO R, Iwai S, Masutani C, Hanaoka F . Error-prone bypass of certain DNA lesions by the human DNA polymerase kappa. Genes Dev. 2000; 14(13):1589-94. PMC: 316741. View

12.

Zhang Y, Yuan F, Xin H, Wu X, Rajpal D, Yang D . Human DNA polymerase kappa synthesizes DNA with extraordinarily low fidelity. Nucleic Acids Res. 2000; 28(21):4147-56. PMC: 113146. DOI: 10.1093/nar/28.21.4147. View

13.

Nelson J, Lawrence C, HINKLE D . Thymine-thymine dimer bypass by yeast DNA polymerase zeta. Science. 1996; 272(5268):1646-9. DOI: 10.1126/science.272.5268.1646. View

14.

Albertella M, Lau A, OConnor M . The overexpression of specialized DNA polymerases in cancer. DNA Repair (Amst). 2005; 4(5):583-93. DOI: 10.1016/j.dnarep.2005.01.005. View

15.

Sieber O, Heinimann K, Tomlinson I . Genomic stability and tumorigenesis. Semin Cancer Biol. 2004; 15(1):61-6. DOI: 10.1016/j.semcancer.2004.09.005. View

16.

Lawrence C, HINKLE D . DNA polymerase zeta and the control of DNA damage induced mutagenesis in eukaryotes. Cancer Surv. 1996; 28:21-31. View

17.

Ceppi P, Novello S, Cambieri A, Longo M, Monica V, Lo Iacono M . Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2009; 15(3):1039-45. DOI: 10.1158/1078-0432.CCR-08-1227. View

18.

Bavoux C, Leopoldino A, Bergoglio V, O-Wang J, Ogi T, Bieth A . Up-regulation of the error-prone DNA polymerase {kappa} promotes pleiotropic genetic alterations and tumorigenesis. Cancer Res. 2005; 65(1):325-30. View

19.

Gueranger Q, Stary A, Aoufouchi S, Faili A, Sarasin A, Reynaud C . Role of DNA polymerases eta, iota and zeta in UV resistance and UV-induced mutagenesis in a human cell line. DNA Repair (Amst). 2008; 7(9):1551-62. DOI: 10.1016/j.dnarep.2008.05.012. View

20.

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View